The Covid vaccine from Pfizer / BioNTech laboratories has ” not yet “ need to be adapted to the new variants of the coronavirus in circulation, assured during a press conference, this Monday, August 9, the boss of BioNTech, advocating instead a “Third dose”.
“It is possible that in the next six to twelve months, a variant will emerge and require adaptation of the vaccine, but this is not yet the case”Ugur Sahin told Berlin.
“Making a decision now could turn out to be wrong, if in three or six months another variant dominates”, he added.
Large real-life study confirms Pfizer vaccine 95% effective
According to him, such a decision should only be made if the “Existing vaccine is not effective or not optimal”.
Gold, “For now, we know that a booster with the basic formula is quite sufficient”, underlined Ugur Sahin.
“Encouraging results” for a 3rd dose
Consequently, “The best approach to manage this situation is to continue with a booster dose” in order to strengthen the immunity granted by the vaccine, he added.
Pfizer and BioNTech also mentioned in early July “Encouraging results” trials for a third dose and plan to seek authorization for a third dose of their vaccine in the United States and Europe.
Ugur Sahin was speaking during the presentation of BioNTech’s second quarter financial results.
7.3 billion euros in turnover
Since the beginning of the year, this German laboratory has already recorded 7.3 billion euros in turnover, against 69.4 million euros over the same period last year, before the development of the serum against Covid-19.
This considerable increase is “Mainly due to the rapid increase in the supply of vaccine against Covid-19 all over the world”, he explained.
Pierre, immunocompromised: “I can only count on collective immunity to find a normal life”
BioNTech has indeed delivered more than a billion doses since the start of the year and expects to reach 2.2 billion by the end of 2021.
With its vaccine against Covid-19 alone, BioNTech hopes to achieve a turnover of nearly 16 billion euros this year.
Forecasts considerably raised: in May the laboratory forecast only 9.8 billion euros of annual turnover.